Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 5/20 | 0.60 |
| ▸ | CTSL | P07711 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31235825 | 1.00 | CTSV (0.60) | CTSVCTSLPOLBSENP8SENP7 | |
| SCHEMBL8316504 | 0.89 | CTSV (0.61) | CTSVCTSLPOLBSENP8SENP7 | |
| SCHEMBL28257932 | 0.88 | CTSV (0.63) | CTSVCTSLPOLBSENP8SENP7 | |
| SCHEMBL11922562 | 0.88 | CTSV (0.53) | CTSVCTSLL3MBTL1NPC1CYP19A1 | |
| SCHEMBL5065157 | 0.87 | CTSV (0.50) | CTSVCTSLPOLBSENP8SENP7 | |
| SCHEMBL2682298 | 0.86 | CTSV (0.49) | CTSVCTSLPOLBPTGESCYP19A1 | |
| SCHEMBL4222265 | 0.86 | CTSV (0.58) | CTSVCTSLPOLBSENP8SENP7 | |
| SCHEMBL1137268 | 0.85 | PTGES (0.57) | CTSVCTSLPOLBPTGESNPC1 | |
| SCHEMBL13504298 | 0.85 | CTSV (0.54) | CTSVCTSLPOLBPTGESMRGPRX4 | |
| SCHEMBL19035902 | 0.85 | CTSV (0.57) | CTSVCTSLPOLBSENP8SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021231400-A1 | BIS-ARYL ETHERS CONTAINING N-ACYL AZETIDINE AS EGFR/HER2 INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| CN-106068262-A | Quinazoline derivant and preparation method thereof and in application pharmaceutically | 四川海思科制药有限公司 | 2016-11-02 | — | — | CN | disclosed |
| WO-2015154725-A1 | QUINAZOLINE DERIVATIVE AND PREPARATION METHOD AND USE IN MEDICINE THEREOF | 四川海思科制药有限公司 | 2015-10-15 | — | — | WO | disclosed |
| US-8242140-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-14 | — | — | US | disclosed |
| EP-2417130-A2 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF | SANOFI (FR) | 2012-02-15 | — | — | EP | disclosed |
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| WO-2010116088-A2 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | WO | disclosed |
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286131-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2B | CTSV 877/4885CTSL 978/4885POLB 15/4885 |
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | CTSV 948/4885CTSL 1316/4885POLB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.